Choroidal Neovascularization Market Size, Share, Trends, Growth Outlook

Choroidal Neovascularization Market is estimated to increase at a growth rate of 6.5% CAGR over the forecast period from 2024 to 2030.

The global Choroidal Neovascularization Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Diagnosis (Fluorescein Angiography, Optical Coherence Tomography, Others), By Treatment (Anti-VEGF, Photodynamic Therapy, Thermal Laser, Others), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others).

An Introduction to Choroidal Neovascularization Market in 2024

The Choroidal Neovascularization Market comprises pharmaceuticals, biologics, and interventional therapies developed to treat abnormal blood vessel growth in the choroid layer of the eye, a condition often associated with age-related macular degeneration (AMD) and other retinal disorders. These treatments include anti-VEGF drugs, photodynamic therapy, laser therapy, and surgical interventions aimed at preserving vision and preventing vision loss due to choroidal neovascularization. In 2024, this market emphasizes innovative ocular drug delivery systems, combination therapies, gene therapies, and emerging treatment modalities, enhancing visual outcomes and patient quality of life.

Choroidal Neovascularization Market Competitive Landscape

The global Choroidal Neovascularization Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Choroidal Neovascularization Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Choroidal Neovascularization Industry include- AbbVie.Inc, AstraZeneca Plc, Bristol-Myers Squibb Co., Dr. Reddy's Laboratories Ltd, Endo International plc, Mylan N.V., Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd.

Choroidal Neovascularization Market Trend: Advancements in Imaging Technologies and Diagnostic Modalities

A prominent trend in the choroidal neovascularization (CNV) market is the continuous advancements in imaging technologies and diagnostic modalities for accurate and early detection of CNV lesions. With improvements in optical coherence tomography (OCT), fluorescein angiography (FA), and indocyanine green angiography (ICGA), healthcare providers can visualize CNV lesions with high resolution and precision, enabling early diagnosis, characterization, and monitoring of disease progression. Moreover, the development of novel imaging biomarkers and artificial intelligence (AI)-based algorithms holds promise for improving diagnostic accuracy, facilitating treatment decision-making, and optimizing patient outcomes in CNV management.

Choroidal Neovascularization Market Driver: Aging Population and Age-related Macular Degeneration (AMD) Burden

A key driver propelling the choroidal neovascularization market is the aging population demographic and the associated burden of age-related macular degeneration (AMD), a leading cause of CNV development. As the global population ages, the prevalence of AMD and its complications, including CNV-associated vision loss, continues to rise, driving the demand for effective diagnostic and therapeutic solutions. The increasing incidence of AMD-related CNV underscores the importance of early detection, timely intervention, and personalized treatment approaches to preserve visual function and improve quality of life for affected individuals, stimulating market growth and innovation in CNV management.

Choroidal Neovascularization Market Opportunity: Development of Novel Therapeutic Modalities and Targeted Therapies

An emerging opportunity in the choroidal neovascularization market lies in the development of novel therapeutic modalities and targeted therapies for CNV management. While anti-vascular endothelial growth factor (anti-VEGF) agents have revolutionized the treatment landscape for CNV, there remains a need for alternative treatment options that address the limitations of current therapies, such as treatment resistance, treatment burden, and long-term efficacy. Researchers and pharmaceutical companies are exploring innovative approaches, including gene therapy, small molecule inhibitors, and combination therapies, to target alternative pathways involved in CNV pathogenesis and angiogenesis, offering potential benefits in terms of treatment response, durability, and patient outcomes. By investing in research and development efforts focused on novel therapeutic targets and delivery systems, stakeholders can unlock new treatment paradigms and address unmet medical needs in CNV management.

Market Share Analysis: Treatment - Anti-VEGF is the fastest growing segment in the Choroidal Neovascularization industry

Among treatments for choroidal neovascularization (CNV), anti-VEGF therapy is experiencing rapid growth. CNV is a leading cause of vision loss in various retinal conditions, including age-related macular degeneration (AMD). Anti-VEGF agents such as ranibizumab, aflibercept, and bevacizumab have revolutionized the management of CNV by targeting vascular endothelial growth factor (VEGF), a key mediator of angiogenesis and vascular permeability. These drugs are administered via intravitreal injections and have demonstrated remarkable efficacy in improving visual acuity and reducing CNV-related complications. As the aging population grows and the prevalence of AMD and other retinal diseases increases, there is a rising demand for effective treatments that can preserve and restore vision in affected individuals. Anti-VEGF therapy has become the standard of care for CNV due to its proven benefits and relatively favorable safety profile. Hospitals, specialty clinics, and homecare settings are witnessing a surge in the utilization of anti-VEGF agents for the treatment of CNV, reflecting the growing adoption of this innovative therapeutic approach. Furthermore, advancements in drug delivery techniques and the development of novel anti-VEGF agents continue to drive the rapid growth of anti-VEGF therapy in the management of CNV, offering hope for improved visual outcomes and quality of life for patients with this sight-threatening condition.

Choroidal Neovascularization Market Segmentation

By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Choroidal Neovascularization Companies

AbbVie.Inc
AstraZeneca Plc
Bristol-Myers Squibb Co.
Dr. Reddy's Laboratories Ltd
Endo International plc
Mylan N.V.
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
* List not Exhaustive

Reasons to Buy the Choroidal Neovascularization Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Choroidal Neovascularization Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Choroidal Neovascularization Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Choroidal Neovascularization Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Choroidal Neovascularization Market Size Outlook, $ Million, 2021 to 2030
3.2 Choroidal Neovascularization Market Outlook by Type, $ Million, 2021 to 2030
3.3 Choroidal Neovascularization Market Outlook by Product, $ Million, 2021 to 2030
3.4 Choroidal Neovascularization Market Outlook by Application, $ Million, 2021 to 2030
3.5 Choroidal Neovascularization Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Choroidal Neovascularization Industry
4.2 Key Market Trends in Choroidal Neovascularization Industry
4.3 Potential Opportunities in Choroidal Neovascularization Industry
4.4 Key Challenges in Choroidal Neovascularization Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Choroidal Neovascularization Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Choroidal Neovascularization Market Outlook by Segments
7.1 Choroidal Neovascularization Market Outlook by Segments, $ Million, 2021- 2030
By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others
8 North America Choroidal Neovascularization Market Analysis and Outlook To 2030
8.1 Introduction to North America Choroidal Neovascularization Markets in 2024
8.2 North America Choroidal Neovascularization Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Choroidal Neovascularization Market size Outlook by Segments, 2021-2030
By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others
9 Europe Choroidal Neovascularization Market Analysis and Outlook To 2030
9.1 Introduction to Europe Choroidal Neovascularization Markets in 2024
9.2 Europe Choroidal Neovascularization Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Choroidal Neovascularization Market Size Outlook by Segments, 2021-2030
By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others
10 Asia Pacific Choroidal Neovascularization Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Choroidal Neovascularization Markets in 2024
10.2 Asia Pacific Choroidal Neovascularization Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Choroidal Neovascularization Market size Outlook by Segments, 2021-2030
By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others
11 South America Choroidal Neovascularization Market Analysis and Outlook To 2030
11.1 Introduction to South America Choroidal Neovascularization Markets in 2024
11.2 South America Choroidal Neovascularization Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Choroidal Neovascularization Market size Outlook by Segments, 2021-2030
By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others
12 Middle East and Africa Choroidal Neovascularization Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Choroidal Neovascularization Markets in 2024
12.2 Middle East and Africa Choroidal Neovascularization Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Choroidal Neovascularization Market size Outlook by Segments, 2021-2030
By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie.Inc
AstraZeneca Plc
Bristol-Myers Squibb Co.
Dr. Reddy's Laboratories Ltd
Endo International plc
Mylan N.V.
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Diagnosis
Fluorescein Angiography
Optical Coherence Tomography
Others
By Treatment
Anti-VEGF
Photodynamic Therapy
Thermal Laser
Others
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others